Adverse effects, pharmacological interactions, and cardiovascular drugs in COVID-19 treatment

Eduardo Chuquiure-Valenzuela, Departamento de Cardiología Adultos, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México
Patricia Chuquiure-Valenzuela, Cardiovascular Post-Surgical Unit, National Institute of Child Health, Lima, Peru
María J. Chuquiure-Gil, Escuela de Medicina, Instituto tecnológico y de estudios superiores de Monterrey, Monterrey, México
María P. Bobadilla-Chuquiure, School of Medicine, Cayetano Heredia University, Lima, Peru
Javier Chuquiure-Valenzuela, Institute of Cardiology and Cardiovascular Surgery, Juaneda Miramar Hospital, Palma de Mallorca, España
Eduardo Chuquiure-Lardizabal, School of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru

In severe coronavirus disease (COVID)-19 patients, an extraordinary systemic inflammatory response is seen. It could impact in multiple organ disorders, specially a severe myocardial injury, an acute myocarditis results in focal or global myocardial inflammation and necrosis. Those events can be present in healthy subjects or cardiovascular (CV) patients. It is clinically associated with ventricular dysfunction exacerbation or worsening and tachyarrhythmias. It is also related to a poor outcome for CV patients with ischemic heart disease, hypertensión, and heart failure. COVID-19 patients require multiple and complex treatment that alleviates symptoms, the vast variety of agents interacts with diseases and CV drugs. Our purpose is to correlate in guidance synopsis: Adverse effects, pharmacological interactions, and CV drugs in COVID-19 treatment.

Keywords: Cardiovascular drugs. Pharmacology interactions. Adverse effects. COVID-19.